Full Text View
Tabular View
No Study Results Posted
Related Studies
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Cancer Institute (NCI).   Recruitment status was  Active, not recruiting

First Received on June 6, 2001.   Last Updated on June 19, 2010   History of Changes
Sponsor: German Low Grade Lymphoma Study Group
Collaborators: European Organization for Research and Treatment of Cancer - EORTC
Gruppo Italiano Studio Linfomi
Groupe d'Etudes de Lymphomes de L'Adulte
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00016887
  Purpose

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether giving more than one drug (combination chemotherapy) with radiation therapy and peripheral stem cell transplant is more effective than chemotherapy followed by interferon alfa in treating mantle cell lymphoma.

PURPOSE: This randomized phase III trial compares how well chemotherapy followed by radiation therapy, chemotherapy, and peripheral stem cell transplant works compared to chemotherapy plus interferon alfa in treating patients who have stage III or stage IV mantle cell lymphoma.


Condition Intervention Phase
Lymphoma
 Biological: filgrastim
Biological: recombinant interferon alfa
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
 Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lymphoma
Drug Information available for: Dexamethasone Cyclophosphamide Cytarabine hydrochloride Etoposide Dexamethasone acetate Doxiproct plus Interferon alfa-2a Etoposide phosphate Filgrastim Lenograstim Granulocyte colony-stimulating factor Interferon alfa-n1 Cytarabine Melphalan Carmustine Sarcolysin Dexamethasone Sodium Phosphate Melphalan hydrochloride Interferons
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: December 2000
Detailed Description:

OBJECTIVES:

  • Compare the disease-free survival of patients with previously untreated advanced mantle cell lymphoma treated with intensified chemotherapy followed by myeloablative radiochemotherapy and peripheral blood stem cell transplantation (PBSCT) vs standard therapy and interferon alfa maintenance.
  • Compare the overall survival of patients treated with early vs late myeloablative radiochemotherapy and PBSCT.
  • Compare disease-free survival and overall survival of patients treated with this regimen vs historic controls of similar cases.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk factors (ECOG performance status greater than 1, LDH serum level above normal, and/or extranodal lymphoma involvement) and participating center. Patients are randomized to 1 of 2 treatment arms.

  • Induction: All patients receive 4 courses of cytoreductive chemotherapy comprising an anthracycline-containing combination. Patients not achieving complete remission after 4 courses receive 2 additional courses of induction chemotherapy. Patients without at least a partial response after 6 courses discontinue treatment; those with at least a partial response proceed to arm I or II.

Arm I

  • Consolidation: Patients achieving complete or partial remission after 4-6 courses of induction therapy begin intensified chemotherapy within 6 weeks. Patients receive oral dexamethasone daily on days 1-10, carmustine IV on day 2, melphalan IV on day 3, etoposide IV daily and cytarabine IV twice a day on days 4-7. Patients also receive filgrastim (G-CSF) beginning on day 11 and continuing until peripheral blood stem cells (PBSC) are harvested.
  • Within 4-6 weeks after PBSC harvest, patients undergo myeloablative radiochemotherapy comprising radiotherapy on days -6 to -4 and cyclophosphamide IV on days -3 to -2. Patients then undergo PBSC transplantation on day 0.

Arm II

  • Consolidation: Patients receive 2 additional courses of induction chemotherapy as consolidation (for a total of 8 chemotherapy courses).
  • Maintenance: Within 4 weeks after arm II consolidation, patients receive interferon alfa subcutaneously (SC) 3 days a week in the absence of unacceptable toxicity or disease progression or relapse. Patients who experience first relapse or progression during maintenance therapy may receive intensified chemotherapy as in arm I.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 210 patients will be accrued for this study within 5 years.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage III or IV mantle cell lymphoma

    • Previously untreated
  • Not qualified for primary potentially curative radiotherapy

PATIENT CHARACTERISTICS:

Age:

  • 18 to 65 years

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • No impairment of liver function (unless due to lymphoma)
  • Transaminases no greater than 3 times normal
  • Bilirubin no greater than 2.0 mg/dL

Renal:

  • No renal insufficiency
  • Creatinine no greater than 2.0 mg/dL

Cardiovascular:

  • No manifest heart failure or coronary heart disease
  • No severe uncontrolled hypertension

Pulmonary:

  • No chronic lung disease with hypoxemia

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No severe uncontrolled diabetes mellitus

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior interferon
  • No prior organ, bone marrow, or peripheral blood stem cell transplantation

Chemotherapy:

  • No prior cytostatic chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy

Surgery:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00016887

Locations
Belgium
AZ Sint-Jan
Brugge, Belgium, 8000
Italy
Ospedale Civile Alessandria
Alessandria, Italy, I-15100
Sponsors and Collaborators
German Low Grade Lymphoma Study Group
European Organization for Research and Treatment of Cancer - EORTC
Gruppo Italiano Studio Linfomi
Groupe d'Etudes de Lymphomes de L'Adulte
Investigators
Study Chair: Wolfgang Hiddemann, MD, PhD Klinikum der Universitaet Muenchen - Grosshadern Campus
Study Chair: J. C. Kluin-Nelemans, MD, PhD University Medical Centre Groningen
Study Chair: Alessandro Levis, MD Ospedale Civile Alessandria
Study Chair: Achiel Van Hoof, MD AZ Sint-Jan
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00016887     History of Changes
Other Study ID Numbers: CDR0000068609, GER-LGLSG-INTERGROUP-20995, EORTC-20995, GELA-INTERGROUP-20995, GISL-INTERGROUP-20995
Study First Received: June 6, 2001
Last Updated: June 19, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage III mantle cell lymphoma
stage IV mantle cell lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Interferon-alpha
Interferon Alfa-2a
Cytarabine
Interferons
Cyclophosphamide
Melphalan
 Lenograstim
Carmustine
Dexamethasone
Etoposide
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents

ClinicalTrials.gov processed this record on February 12, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services